Trevi Therapeutics (TRVI) Interest Coverage Ratio (2018 - 2022)

Trevi Therapeutics' Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 61.91 for Q1 2026.

• In Q1 2026, Interest Coverage Ratio rose 1.56% year-over-year to 61.91; the TTM figure through Mar 2026 stood at 242.19 (up 21.23% YoY), while the FY2025 annual figure was 0.6, up 86.5% from the prior year.
• Interest Coverage Ratio for Q1 2026 stood at 61.91, down from 39.31 in the prior quarter.
• The five-year high for Interest Coverage Ratio was 159.52 in Q4 2023, with the low at 12243.0 in Q4 2024.
• The 5-year median for Interest Coverage Ratio is 26.51 (2022), against an average of 740.66.
• The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio surged 1295.72% in 2023, then tumbled 7775.0% in 2024.
• Trevi Therapeutics' Interest Coverage Ratio stood at 13.34 in 2022, then soared by 1295.72% to 159.52 in 2023, then sank by 7775.0% to 12243.0 in 2024, then soared by 100.32% to 39.31 in 2025, then slumped by 257.51% to 61.91 in 2026.
• Business Quant data shows TRVI's Interest Coverage Ratio at 61.91 in Q1 2026, 39.31 in Q4 2025, and 14.85 in Q3 2025.